Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ildong, Cellivery To Co-Develop Novel Biologic For Parkinson's

This article was originally published in PharmAsia News

Executive Summary

South Korean pharma firm Ildong and bioventure Cellivery have tied up to jointly develop an early stage, first-in-class therapy for Parkinson's disease using Cellivery's platform technology. The two hope the partnership will fundamentally change the therapeutic approach to the neurodegenerative disease.

You may also be interested in...



Cellivery IPO To Fund Potential First-In-Class Parkinson's Asset, May Speed Licensing Deal

Marking the first Korean company to launch an initial public offering on the recommendation of its lead broker, Cellivery Therapeutics is slated to use the upcoming proceeds to progress preclinical trials of its lead assets for Parkinson's disease and pancreatic cancer, which the company aims to license out to global partners in the early development stages.

From Science To Commercialization: How Genexine Is Making The Shift

Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.

Korean Industry Demands Bold Support Amid US Policy Moves

As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC089366

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel